Inactive Instrument

News BioCardia Inc Nasdaq

Equities

US09060U1016

End-of-day quote Nasdaq Other stock markets
- ^USD	-

05-21	BioCardia to Implement 1-for-15 Reverse Stock Split; Shares Fall After Hours	MT
05-14	Transcript : BioCardia, Inc., Q1 2024 Earnings Call, May 14, 2024

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioCardia to Implement 1-for-15 Reverse Stock Split; Shares Fall After Hours	05-21	MT
BioCardia Announces Reverse Stock Split	05-21	AQ
Transcript : BioCardia, Inc., Q1 2024 Earnings Call, May 14, 2024	05-14
BioCardia : Reports First Quarter 2024 Business Highlights and Financial Results	05-14	PU
BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024	05-09	AQ
BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes	05-01	AQ
BioCardia, Inc. Announces the Primary Endpoint Results of the Open Label Roll-In Cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial	05-01	CI
Transcript : BioCardia, Inc. - Special Call	04-30
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort	04-25	AQ
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort	04-25	CI
Transcript : BioCardia, Inc., 2023 Earnings Call, Mar 27, 2024	03-27
BioCardia, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
BioCardia : Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results	03-27	PU
BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024	03-20	AQ
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership	03-13	AQ
BioCardia, Inc. and StemCardia, Inc. Announce Long-Term Partnership to Advance StemCardia?s Investigational Pluripotent Stem Cell Product Candidate for Treatment of Heart Failure	03-13	CI
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study	03-12	AQ
BioCardiaAnnounces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study	03-12	CI
BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure	03-04	AQ
Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure	03-04	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News BioCardia Inc Nasdaq

Equities

US09060U1016

Summary

Filters